Introduction
When evaluating the risks to human populations from particular environmental exposures, it is important to approach the analysis with an integrated investigation. The most informative approach is to combine environmental exposure monitoring with biological techniques that can provide insight into actual internal human exposure, dose to a relevant target tissue, markers of biological effect and, ultimately, measures of human disease. Although the most useful data on which to conduct a risk assessment may come from epidemiological studies identifying cancer or other human disease, one would like to identify potential adverse exposures before significant numbers ofindividuals are affected. Thus, it seems reasonable to develop and characterize markers of biological effect for identifying adverse exposure scenarios.
Because of the association of mutational events with the etiology of cancer, a number of genetic damage assays have been used to detect the potential ofvarious chemicals and physical agents to cause genotoxic effects. The range and types of mutational events associated with cancer and other diseases include point mutations, deletions, translocations, mitotic recombination, gene conversion, gene amplification, and aneuploidy. It seems obvious that an analysis ofvarious genetic assays should include an understanding of the spectrum of genetic damage detected by that assay.
In human population monitoring, the quantitative analysis of mutation events that affect gene function is limited to those genes whose cellular phenotypes can be identified by selection procedures and to those tissues (like blood) that are accessible for analysis. To determine the frequency and types of mutations that can be detected at the hprt gene, we have used the T-cell cloning assay (1, 2) 
In Vivo Assay
Cells were plated in 96-well, round-bottom, microtiter plates (Nunc, Naperville, IL) at cell densities of 1, 2, 5, and 10 cells/well to determine cloning efficiency and at 1-2 x 104 cells/well for hprt mutant selection. Cells were plated in 200 ,L of medium containing 20% growth factor supplement, 20% HL1, 5% CBS, 55% RPMI, and 0.25 pLg/mL PHA with 1 x 104 irradiated feeder cells/well. Growth factor supplement (kindly provided by the University of Vermont; Burlington, VT) is the cell-free supernatant medium used in the lymphokine activated killer-cell therapy. The method for its preparation is reported by Branda et al. (5) . Selection plates were supplemented with 10 AM 6-thioguanine (6-TG, Sigma).
In Vitro Assay
For in vitro treatments, cryopreserved lymphocytes were thawed, washed with fresh medium, and counted, as above. Cells were then placed in tissue culture flasks and gassed with 5% CO2 for overnight culture in a 37°C
incubator. When cells in the Go phase of cell growth were desired for chemical treatment, cells were cultured in RPMI with 10% CBS. For chemical treatments using proliferating cells, 1 ,ug/mL of PHA was added to stimulate the cells into division. The cells were incubated for 21-25 hr, centrifuged, resuspended in RPMI, and counted with a hemocytometer. Cells were prepared at a density of 2 x 106 cells/mL in RPMI, and 5 mL of the cell culture were added to 50 mL centrifuge tubes for treatment. The test agent was added, cultures were gassed with 5% CO2 in air, and placed horizontally in a 37°C incubator for 3 hr. After treatment, cells were centrifuged at 250g and washed three times with 10 mL of RPMI. After the final wash, cells were resuspended in 5 mL RPMI and placed into a 25-cm2 tissue culture flask. The tube was rinsed with 5 mL of 40/10 medium (50% RPMI, 40% HL1, 10% CBS), and the rinse was added to the tissue culture flask. Cells were gassed with 5% CO2 in air and placed in a 37°C CO2 incubator for 2 days.
Two different techniques were used for the mutant expression-mutant selection phases of the experiment. The first technique [standard (6) ], modeled after standard in vitro mutagenesis procedures, involved an expression period during which time the cell culture was maintained in suspension culture. After the expression period, the cells were plated in 96-well plates with the selective agent. The second technique (in situ), developed by O'Neill et al. (7), involved plating cells into the 96-well plates on day 2 after treatment, allowing the cells to grow and the newly induced mutants to be expressed in the 96-well plates. The selection agent was then added to the 96-well tray after the 5-day expression period. Before conducting the in situ protocol, the standard method was used to establish the appropriate concentration range for the chemical treatment.
Scoring
Viable clones were scored using an inverted phase contrast microscope. Selection plates were scored 10-12 days after cloning and were scored a second time 5-7 days later. Survival and cloning efficiency plates were scored 14-15 days after cloning. On those occasions when nonmutant clones were to be isolated for additional culture, these plates were first scored at 10-12 days, clones were isolated, and final scoring was completed at 14-15 days after cloning. Survival and cloning efficiency with and without selection were calculated using the Poisson distribution (po = e -X, where po is the fraction of wells without colony growth). Survival and cloning efficiency with and without selection = -lnPo x, where x is the average number of cells plated per well. The mutant frequency is the ratio of the cloning efficiencies in the presence and absence of 6TG selection.
Mutant Isolation
The hprt mutants were isolated from selected experiments. These cells were cultured for cryopreservation and molecular analysis. About one-half of the total volume of media, 0.10 mL, was removed and discarded from the top of each well containing a clone selected for isolation. The clone was then carefully resuspended using a 1-mL pipet and transferred to a single well in another 96-well microtiter plate. The Figure 1 , the multiplex PCR analysis was used to determine which mutants contained total or partial hprt gene deletions. Those mutants were cultured to the extent of their viability and prepared for cryopreservation and further molecular analyses. Mutants that did not appear to result from deletions were not cultured further.
Cryopreservation of Mutants
One-half of the media was carefully removed (and discarded) from the top of each mutant to be cryopreserved. Cells were resuspended and counted using a hemocytometer. If the cell density was less than 2 x 106 cells/mL, the cells were centrifuged for 10 min at 250g and resuspended in the supernatant at 2 x 106 cells/mL. A total of 0.9 mL of cells was added to a cryogenic vial, mixed gently with 0.9 mL of freezing media (84% CBS, 16% dimethyl sulfoxide), and the vial was placed in a freezing collar (Taylor-Wharton) for cryopreservation. The freezing collar was set in position E to allow the cells to cool at 1°C min to a temperature of -80°C and then placed in liquid nitrogen.
In some cases, mutants did not grow to a concentration that could be frozen in this manner. In those cases, cells were counted, centrifuged for 10 min at 250g, and resuspended in 1.8 mL of 90% CBS, 10% dimethyl sulfoxide containing a concentration of irradiated feeder cells required to bring the overall cell density (lymphocytes and feeder cells) to 3 x 106 cells/mL.
Multiplex PCR Analysis
Crude cellular extracts were prepared by a modification of the method described by Higuchi (8 (9) . After 33 cycles, one-half of the reaction was analyzed by agarose gel (1.4%) electrophoresis for the presence of individual hprt exons and changes in exon fragment size. After the initial screening, larger amounts of crude extract at 2 x 106 cells/mL were prepared for further analyses. Direct DNA sequencing of PCR products was performed using primers and conditions described previously (10,11).
Strategy for Breakpoint Analysis Figure 1 shows our strategy for identifying and analyzing hprt deletion mutations. Crude cell extracts were first analyzed by multiplex hprt PCR as described above. Those mutants that showed a wild-type pattern were not studied further. Those that showed a weak signal, or no signal, were candidates for containing total hprt gene deletions. The same result, however, would be obtained if the PCR reaction failed because of, for example, inhibitors from the extracts or inadequate DNA. These extracts were, therefore, examined in a duplex PCR reaction in which an unlinked gene segment (K-ras on chromosome 12) was coamplified with hprt exon 6 (12) . If a wild-type pattern or no K-ras signal was seen after agarose gel electrophoresis, the mutant was not studied further. If K-ras was present, but the hprt exon 6 was absent, the mutation was a total hprt gene deletion. Flanking primer pairs located approximately 300 kb 3' and 350 kb 5' of the hprt gene were then used in a duplex PCR assay with the K-ras primers to determine how far the deletions extend beyond hprt (12) .
If the original multiplex hprt PCR showed an alteration in an exon fragment size, that exon was individually amplified and sequenced (11) to determine the deletion size and the characteristics of the deletion junction. Hypotheses concerning mechanisms were then formed for testing.
Finally, when the multiplex hprt PCR revealed missing exon fragment(s), additional PCR reactions with intronic primer pairs and Southern blot hybridization were used to localize the breakpoints. The breakpoint junction was then amplified by PCR for DNA sequence analysis.
Results and Discussion
The mutant frequency data for 19 separate determinations is shown in Table 1 . The mean mutant frequency for all samples was 9.5 x 10-6, with a range of 2.1-27 x 10-6. In addition to the mutant frequency, the age, sex, smoking status, nonselective cloning efficiency, number of cells plated for mutant selection, and the total number of mutants are presented. Although our database is small, it does appear that, as has been shown by other laboratories (13, 14) , there is an age-dependent increase in the mean mutant frequency (Fig. 2) . There does not appear to be an increased hprt mutant frequency among smokers. To date, we have analyzed 165 mutants from 5 individuals using the multiplex PCR technique. Of these, 135 showed no change, 18 showed partial deletions and 12 showed total deletions of the hprt gene.
Examples of multiplex hprt PCR patterns are shown in Figure 3 . GM131 is an apparently normal lymphoblastoid cell line with an intact hprt gene and exhibits the wild-type tolerated. This suggests that the difference is not due to an inability of the hprt locus to sustain large deletions. Furthermore, our earlier investigations of tk mechanisms of mutagenesis (16) suggest that a significant number of tk mutants result from homologous mitotic recombination.
In the present studies, we have demonstrated our ability to produce mutant frequency data similar to that published by other laboratories. We have also begun to evaluate the range and types of genetic damage detected by the human T-lymphocyte hprt assay. Based on our data and that of other laboratories, we know that the spectrum of genetic damage detected includes point mutations (17, 18) and deletions ranging from a few base pairs, one or more exons, the entire hprt gene and extensive numbers of base pairs outside of the hprt gene. We are currently working to define the size of the maximum-tolerated deletion around the hprt gene as well as to determine the mechanism(s) of deletion formation.
